ArticleAdvances in therapy2022

Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China.

Haijing Guan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.